CD40 and neoplasm: Flow cytometry analyses (Fig. 5c) showed that IRE-treated KRAS* cells increased the expression of DC activation/maturation markers CD40, CCR7, and CD86 by 72 ± 2%, 52 ± 4%, and 51 ± 4% (mean ± SEM, n = 3), respectively, compared to live KRAS* cells, in the tumor cell-exposed DCs (p < 0.01, two-sided Student’s t-test).